67
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Somatic mutations in the spliceosome gene ZRSR2 — located on the X chromosome — are associated with myelodysplastic syndrome (MDS). ZRSR2 is involved in the recognition of 3΄ splice site during the early stages of spliceosome assembly; however, its precise role in RNA splicing has remained unclear. Here, we characterize ZRSR2 as an essential component of the minor spliceosome (U12-dependent) assembly. shRNA mediated knockdown of ZRSR2 leads to impaired splicing of the U12-type introns, and RNA-Sequencing of MDS bone marrow reveals that loss of ZRSR2 activity causes increased mis-splicing. These splicing defects involve retention of the U12-type introns while splicing of the U2-type introns remain mostly unaffected. ZRSR2 deficient cells also exhibit reduced proliferation potential and distinct alterations in myeloid and erythroid differentiation in vitro. These data identify a specific role for ZRSR2 in RNA splicing and highlight dysregulated splicing of U12-type introns as a characteristic feature of ZRSR2 mutations in MDS.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: not found
          • Article: not found

          Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

            Recent advances have highlighted extensive phenotypic and functional similarities between normal stem cells and cancer stem cells. This raises the question of whether disease therapies can be developed that eliminate cancer stem cells without eliminating normal stem cells. Here we address this issue by conditionally deleting the Pten tumour suppressor gene in adult haematopoietic cells. This led to myeloproliferative disease within days and transplantable leukaemias within weeks. Pten deletion also promoted haematopoietic stem cell (HSC) proliferation. However, this led to HSC depletion via a cell-autonomous mechanism, preventing these cells from stably reconstituting irradiated mice. In contrast to leukaemia-initiating cells, HSCs were therefore unable to maintain themselves without Pten. These effects were mostly mediated by mTOR as they were inhibited by rapamycin. Rapamycin not only depleted leukaemia-initiating cells but also restored normal HSC function. Mechanistic differences between normal stem cells and cancer stem cells can thus be targeted to deplete cancer stem cells without damaging normal stem cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The role of mutations in epigenetic regulators in myeloid malignancies.

              Recent genomic studies have identified novel recurrent somatic mutations in patients with myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). In some cases these mutations occur in genes with known roles in regulating chromatin and/or methylation states in haematopoietic progenitors, and in other cases genetic and functional studies have elucidated a role for specific mutations in altering epigenetic patterning in myeloid malignancies. In this Review we discuss recent genetic and functional data implicating mutations in epigenetic modifiers, including tet methylcytosine dioxygenase 2 (TET2), isocitrate dehydrogenase 1 (IDH1), IDH2, additional sex combs-like 1 (ASXL1), enhancer of zeste homologue 2 (EZH2) and DNA methyltransferase 3A (DNMT3A), in the pathogenesis of MPN, MDS and AML, and discuss how this knowledge is leading to novel clinical, biological and therapeutic insights.
                Bookmark

                Author and article information

                Journal
                101528555
                37539
                Nat Commun
                Nat Commun
                Nature communications
                2041-1723
                25 December 2014
                14 January 2015
                2015
                14 July 2015
                : 6
                : 6042
                Affiliations
                [1 ]Cancer Science Institute of Singapore, National University of Singapore, Singapore
                [2 ]Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
                [3 ]Cedars-Sinai Medical Center, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, USA
                [4 ]Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
                [5 ]Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
                [6 ]MLL Munich Leukemia Laboratory, Munich, Germany
                [7 ]Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
                [8 ]Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
                [9 ]National University Cancer Institute, National University Hospital Singapore, Singapore
                Author notes
                Correspondence and requests for materials should be addressed to V.M. ( csivm@ 123456nus.edu.sg ) or to H.Y. ( csiyangh@ 123456nus.edu.sg )
                [†]

                Present address: AstraZeneca, Personalized Healthcare and Biomarkers, Innovative Medicines, Cambridge, UK.

                [*]

                These authors contributed equally to this work.

                Article
                NIHMS647095
                10.1038/ncomms7042
                4349895
                25586593
                9acf2e50-b779-4996-aa61-4ccee2a28e48
                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article